Latest Headlines

Latest Headlines

Medicago facility cranks up for VLP vax production

Vaccine seeding is under way at Medicago's new 97,000-square-foot, plant-based vaccine facility in Research Triangle Park, NC. Less than a year after groundbreaking, the production of vaccines based

Medicago: PhII avian flu vax trial successful

Canada's Medicago says the company's Phase II trial of its vaccine for avian flu elicited a solid immune response and was found to be safe and well tolerated. Notably, the vaccine was equally

Medicago, BU design tobacco vax factories

Efforts to speed up vaccine manufacturing have shifted into overdrive now that flu season is here. Tobacco and virus-like particles are currently in the headlines for efforts geared at developing

DARPA efforts tweak tobacco-based vax making

The Defense Advanced Research Projects Agency is funding four efforts to develop vaccine manufacturing processes based on fast-growing tobacco plants. Under its Blue Angel initiative, begun in May

VLP vax facility aims for 10M doses/month

Medicago USA has been granted $21 million from the Defense Advanced Research Projects Agency and several other military organizations to demonstrate scalable manufacturing of its plant-expressed

Medicago to develop vax facility in NC

Canada's Medicago is developing a 90,000-square-foot facility in Research Triangle Park, North Carolina for the company's VLP plant-based vaccine technology to combat flu. Medicago received the

Medicago shares jump after regulators clear flu trial

In a fresh sign that everything pandemic-related gets swiftly shoved into the biotech spotlight these days, shares of Medicago have been buoyed by its announcement that Canadian regulators have

Medicago gets big backer for tobacco vax

After quietly backing the small Canadian vaccine developer Medicago, the giant tobacco company Philip Morris has stepped up to grab a majority interest in the company. Philip Morris took 49.9 percent

Tobacco giant plants $16M investment in Medicago

Canada's Medicago--which is making vaccines from tobacco--has earned a $16 million investment from tobacco giant Philip Morris. Philip Morris gains a 49.9 percent stake in the developer, along with a